← Back
Data updated: Jun 28, 2026
DAY ONE BIOPHARMS
Pharma Pharmaceuticals
DAY ONE BIOPHARMS is a pharmaceutical company with 1 FDA-approved products.
2024
Since
1
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules
FDA Novel Drug Designations
(2024) 1 Novel 1 Orphan 1 Breakthrough 1 Accelerated 1 Priority Review
See 1 novel approval →
2024 OJEMDA (TOVORAFENIB) Orphan · Breakthrough · Priority Review · Accelerated
DAY ONE BIOPHARMS's Key Drugs
DAY ONE BIOPHARMS's core commercial portfolio centers on OJEMDA — its most strategically important drugs approved in the last 15 years.
DAY ONE BIOPHARMS's Recent FDA Approvals
New NDA/BLA approvals for DAY ONE BIOPHARMS over the last two years — novel drugs only, excluding generics and label supplements.
No recent approvals
DAY ONE BIOPHARMS's Therapeutic Areas
Disease areas where DAY ONE BIOPHARMS has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
No indication data
DAY ONE BIOPHARMS Pipeline Snapshot
Active clinical trials for DAY ONE BIOPHARMS across all therapeutic areas, from ClinicalTrials.gov.
No active pipeline data available
Pro Expected Approvals & Milestones
Loading detailed analysis...
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • OJEMDA leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Unlock Full Intelligence
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2024-04-23
- Latest
- 2025-08-27
- Applications
- 2